

**Brand Name:** Enspryng

**Generic:** satralizumab

**Type:** monoclonal antibody

**Year Accepted/Phase:** 2020

**Mechanism:**

Satralizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor. IL-6 is a cytokine involved in the inflammatory process of NMOSD. By inhibiting the IL-6 receptor, satralizumab reduces inflammation and prevents relapses in NMOSD patients.

**Chemical Structure:** N/A

**Indication:**

Enspryng is indicated for the treatment of NMOSD in adult patients who are AQP4 antibody positive.

## **Clinical trials:**

### **SAkuraSky Trial**

**Pubmed:** <https://pubmed.ncbi.nlm.nih.gov/31774956/>

**Purpose:** Evaluate the efficacy and safety of satralizumab in combination with baseline immunosuppressive therapy in patients with NMOSD.

**Dates:** The SAkuraSky trial results were published in 2019.

**Results:** The trial demonstrated that satralizumab, when added to baseline immunosuppressive therapy, significantly reduced the risk of relapse in patients with NMOSD compared to placebo.

**Impact:** The positive results from this trial supported the use of satralizumab as an add-on therapy for NMOSD.

### **SAkuraStar Trial**

**Pubmed:** <https://pubmed.ncbi.nlm.nih.gov/32333898/>

**Purpose:** Evaluate the efficacy and safety of satralizumab as a monotherapy in patients with NMOSD.

**Dates:** The SAkuraStar trial results were published in 2019.

**Results:** The trial demonstrated that satralizumab as a monotherapy significantly reduced the risk of relapse in patients with NMOSD compared to placebo.

**Impact:** The positive results from this trial supported the use of satralizumab as a monotherapy for NMOSD.